Jan. 25, 2013
Heat–activated liposome encapsulated doxorubicin – NIHR Horizon …Heat–activated liposome encapsulated doxorubicin (ThermoDox) for hepatocellular carcinoma.
Zhejiang Hisun Pharma inlicenses China rights to liver cancer drug (ThermoDox) from Celsion Corporation
Celsion Corporation a leading oncology drug development company, and Zhejiang Hisun Pharmaceutical Company Ltd. a leading Chinese pharmaceutical company, today announced that they have entered into a technology development agreement for ThermoDox® for the greater China territory.
ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. For primary liver cancer, ThermoDox® is being evaluated in a 700 patient global Phase III study at 79 clinical sites under an FDA Special Protocol Assessment.
The study is designed to evaluate the efficacy of ThermoDox® in combination with RFA when compared to patients who receive RFA alone…
View original post 1,200 more words